Iterum Therapeutics (ITRM)

Executive Summary

Iterum Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel anti-infectives to address multidrug-resistant bacterial infections. In 2024, the company achieved a landmark FDA approval for ORLYNVAH™ (sulopenem etzadroxil/probenecid), the first and only oral penem antibiotic, indicated for uncomplicated urinary tract infections (uUTIs). This approval marks a significant milestone in combating antibiotic resistance, offering an oral alternative to intravenous therapies. Iterum's pipeline includes sulopenem in various formulations for complicated UTIs, intra-abdominal infections, and other indications, with multiple Phase 3 trials completed. The company is publicly traded (NASDAQ: ITRM) and headquartered in Dublin, Ireland. With a market cap of approximately $1.6 million (estimated), Iterum faces the challenge of commercializing ORLYNVAH and generating revenue, while advancing its pipeline. The recent initiation of a Phase 1 pharmacokinetic study (NCT07092813) in early 2026 highlights ongoing efforts to optimize dosing. Iterum's success hinges on market adoption of ORLYNVAH and potential label expansions.

Upcoming Catalysts (preview)

• Q3 2026ORLYNVAH Commercial Launch Progress and Revenue Guidance80% success
• Q3 2026Phase 1 PK Study Completion for Sulopenem Etzadroxil/Probenecid90% success
• TBDPotential FDA Submission for Complicated UTI Indication50% success